A multicenter Phase I study of OT-C001 in combination with Rituximab in patients with diffuse large B-cell lymphoma (DLBCL)
Latest Information Update: 26 May 2025
At a glance
- Drugs OT C001 (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms C00101 study
Most Recent Events
- 26 May 2025 New trial record
- 22 Apr 2025 According to Onward Therapeutics media release, the company announced that its subsidiary, Emercell SAS, has received Investigational Medicinal Product Dossier (IMPD) approval from the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of OT-C001